LYEL
Lyell Immunopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
LYEL Profile
Lyell Immunopharma, Inc.
A clinical‑stage T-cell reprogramming company that develops curative cell therapies for solid tumors
201 Haskins Way, South San Francisco, California 94080
--
Lyell Immunopharma, Inc., was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company that is expected to enter pivotal trials in 2025 and advance a proprietary next-generation pipeline of autologous chimeric antigen receptor T cell product candidates for patients with hematological malignancies and solid tumors. The company is pioneering new methods aimed at generating T cells that drive durable clinical responses. The patient's living cells are the starting point for the company's investigational CAR T cell therapy, which the company enhances with innovative CAR structures, technologies and manufacturing protocols.
